Search research articles
Contact Us
Filters
Showing results (51-60 of 107) with videos related to
Page
of 11
Sort By:
European Urology
|
December 3, 2019
Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 2020;77:420-33: A Statement from the International Bladder Cancer Network
Stephen B Williams, Peter C Black, Lars Dyrskjøt, et al.
Anticancer Research
|
July 1, 2015
Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma
Danijel Sikic, Sven Wach, Helge Taubert, et al.
Cancers
|
November 26, 2022
The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape
Christian Doehn, Martin Bögemann, Viktor Grünwald, et al.
International Journal of Clinical and Experimental Pathology
|
October 18, 2013
Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk
Anja Rogler, Sabine Hoja, Eileen Socher, et al.
The British Journal of Nutrition
|
November 10, 2022
Lifestyle aspects in a contemporary middle-European cohort of patients undergoing androgen deprivation therapy for advanced prostate cancer: data from the non-interventional LEAN study
Bernd J Schmitz-Dräger, Ekkehardt Bismarck, Dorothee Grammenos, et al.
International Journal of Cancer
|
August 2, 2020
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial
Michael Staehler, Andrej Panic, Peter J Goebell, et al.
Oncology Research and Treatment
|
January 21, 2019
Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study
Peter J Goebell, Edwin Hermann, Ulrich Kube, et al.
Clinical Genitourinary Cancer
|
August 1, 2018
Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry
Peter J Goebell, Michael Staehler, Lothar Müller, et al.
Urologic Oncology
|
January 14, 2023
Editorial: Cutting edge basic and clinical bladder cancer research - the IBCN updates
Peter J Goebell, Ashish M Kamat, Peter C Black, et al.
Journal of Clinical Medicine
|
August 12, 2022
New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial
Katja Schlichtig, Lisa Cuba, Pauline Dürr, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 107) with videos related to
Sort By:
Page
of 11
European Urology
|
December 3, 2019
Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 2020;77:420-33: A Statement from the International Bladder Cancer Network
Stephen B Williams, Peter C Black, Lars Dyrskjøt, et al.
Anticancer Research
|
July 1, 2015
Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma
Danijel Sikic, Sven Wach, Helge Taubert, et al.
Cancers
|
November 26, 2022
The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape
Christian Doehn, Martin Bögemann, Viktor Grünwald, et al.
International Journal of Clinical and Experimental Pathology
|
October 18, 2013
Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk
Anja Rogler, Sabine Hoja, Eileen Socher, et al.
The British Journal of Nutrition
|
November 10, 2022
Lifestyle aspects in a contemporary middle-European cohort of patients undergoing androgen deprivation therapy for advanced prostate cancer: data from the non-interventional LEAN study
Bernd J Schmitz-Dräger, Ekkehardt Bismarck, Dorothee Grammenos, et al.
International Journal of Cancer
|
August 2, 2020
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial
Michael Staehler, Andrej Panic, Peter J Goebell, et al.
Oncology Research and Treatment
|
January 21, 2019
Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study
Peter J Goebell, Edwin Hermann, Ulrich Kube, et al.
Clinical Genitourinary Cancer
|
August 1, 2018
Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry
Peter J Goebell, Michael Staehler, Lothar Müller, et al.
Urologic Oncology
|
January 14, 2023
Editorial: Cutting edge basic and clinical bladder cancer research - the IBCN updates
Peter J Goebell, Ashish M Kamat, Peter C Black, et al.
Journal of Clinical Medicine
|
August 12, 2022
New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial
Katja Schlichtig, Lisa Cuba, Pauline Dürr, et al.
Page
of 11